<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Expert consensus on the management of immunosuppression for specific skin cancer scenarios</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Expert consensus on the management of immunosuppression for specific skin cancer scenarios</h1>
<div class="graphic"><div class="figure"><div class="ttl">Expert consensus on the management of immunosuppression for specific skin cancer scenarios</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1" colspan="2" rowspan="2">Skin cancer scenario*</td> <td class="subtitle1" colspan="3">Level of reduction of immunosuppression to consider<sup>Δ</sup></td> </tr> <tr> <td class="subtitle2">Kidney allograft</td> <td class="subtitle2">Heart allograft</td> <td class="subtitle2">Liver allograft</td> </tr> <tr> <td>1.</td> <td>No history of actinic keratosis or skin cancer</td> <td>None<sup>◊</sup></td> <td>None<sup>◊</sup></td> <td>None<sup>◊</sup></td> </tr> <tr> <td>2.</td> <td> <p>History of actinic keratosis</p> <ul> <li>No risk of mortality </li> <li>Marker for increased skin cancer risk in future </li> </ul> </td> <td>None</td> <td>None<sup>◊</sup></td> <td>None<sup>◊</sup></td> </tr> <tr> <td>3.</td> <td> <p>History of ≤1 NMSC per year</p> <ul> <li>Negligible risk of mortality, ≤1 minor surgical procedure per year </li> <li>Patients handle this with ease </li> <li>Warning sign of possible future skin cancers </li> </ul> </td> <td>Mild</td> <td>None</td> <td>Mild<sup>◊</sup></td> </tr> <tr> <td>4.</td> <td> <p>History of two to five NMSCs per year</p> <ul> <li>Zero to five percent risk of mortality over three years, minor-moderate surgical procedure two to five times per year </li> <li>Patients can usually handle this, but it starts to bother them </li> <li>Likelihood of numerous future skin cancers </li> </ul> </td> <td>Mild<sup>◊</sup></td> <td>Mild</td> <td>Mild</td> </tr> <tr> <td>5.</td> <td> <p>History of 6 to 10 NMSCs per year</p> <ul> <li>One percent risk of mortality over three years, minor-moderate surgical procedure 6 to 10 times per year </li> <li>Patients can usually handle this, but it bothers them </li> <li>High likelihood of numerous future skin cancers </li> </ul> </td> <td>Mild<sup>◊</sup></td> <td>Mild<sup>◊</sup></td> <td>Mild</td> </tr> <tr> <td>6.</td> <td> <p>History of 11 to 25 NMSCs per year</p> <ul> <li>Two percent risk of mortality over three years, minor-moderate surgical procedure 11 to 25 times per year </li> <li>This level of morbidity causes moderate distress and moderate disfigurement, depression may begin </li> <li>High likelihood of severe future skin cancers </li> </ul> </td> <td>Mild<sup>◊</sup></td> <td>Mild<sup>◊</sup></td> <td>Mild</td> </tr> <tr> <td>7.</td> <td> <p>History of &gt;25 NMSCs per year</p> <ul> <li>Five percent risk of mortality over three years, moderate-severe surgical procedure &gt;25 times per year </li> <li>This level of morbidity causes severe distress and disfigurement </li> <li>Patients question whether transplant was worth it; depression is common </li> <li>High likelihood of severe and possibly life-threatening future skin cancers </li> </ul> </td> <td>Moderate</td> <td>Mild</td> <td>Moderate</td> </tr> <tr> <td>8.</td> <td> <p>Individual high-risk skin cancer: 1 percent mortality over three years</p> <ul> <li>Average-risk SCC </li> <li>Cutaneous and oral KS </li> <li>Stage IA melanoma<sup>§</sup> </li> </ul> </td> <td>Mild<sup>◊</sup></td> <td>None</td> <td>Mild</td> </tr> <tr> <td>9. </td> <td> <p>Individual high-risk skin cancer: 5 percent mortality over three years</p> <ul> <li>Moderate-risk SCC </li> <li>Stage IB melanoma<sup>§</sup> </li> </ul> </td> <td>Mild</td> <td>Mild</td> <td>Mild</td> </tr> <tr> <td>10.</td> <td> <p>Individual high-risk skin cancer: 10 percent mortality over three years</p> <ul> <li>High-risk SCC </li> <li>Early Merkel cell carcinoma </li> <li>Stage IIA melanoma<sup>§</sup> </li> </ul> </td> <td>Moderate</td> <td>Mild</td> <td>Moderate</td> </tr> <tr> <td>11.</td> <td> <p>Individual high-risk skin cancer: 25 percent mortality over three years</p> <ul> <li>Very high-risk SCC </li> <li>Stage IIB melanoma<sup>§</sup> </li> </ul> </td> <td>Moderate</td> <td>Mild</td> <td>Moderate</td> </tr> <tr> <td>12.</td> <td> <p>Individual high-risk skin cancer: 50 percent mortality over three years</p> <ul> <li>Metastatic SCC </li> <li>Stage IIC/III melanoma<sup>§</sup> </li> <li>Aggressive Merkel cell carcinoma </li> <li>Visceral KS </li> </ul> </td> <td>Severe<sup>◊</sup></td> <td>Moderate</td> <td>Moderate</td> </tr> <tr> <td>13.</td> <td> <p>Individual high-risk skin cancer: 90 percent mortality over three years</p> <ul> <li>Untreatable metastatic SCC </li> <li>Stage IV melanoma<sup>§</sup> </li> <li>Metastatic Merkel cell carcinoma </li> </ul> </td> <td>Severe<sup>◊</sup></td> <td>Severe</td> <td>Severe</td> </tr> </tbody></table></div><div class="graphic_footnotes">NMSC: nonmelanoma skin cancer; SCC: squamous cell carcinoma; KS: Kaposi's sarcoma.<br/>* Estimates of mortality risk are derived from data in immunocompetent patients; risk may be higher in immunosuppressed patients.<br/>Δ Appropriate level of reduction of immunosuppression should be individualized on the basis of specific patient- and tumor-related data.<br/><font class="lozenge">◊</font> Unanimous opinion.<br/>§ Melanoma staging derived from the American Joint Commission on Cancer.</div><div class="graphic_reference">Otley CC, Berg D, Ulrich C, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 2006; 154:395. Copyright © 2006. Reproduced with permission of John Wiley &amp; Sons, Inc.</div><div id="graphicVersion">Graphic 76140 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
